Chimerism after allogeneic hematopoietic cell transplantation in childhood acute lymphoblastic leukemia

Bone Marrow Transplantation

Volumn 18, Issue 6, 1996, Pages 1161-1165

  Ramirez M ^a   Diaz M A ^a   Garcia Sanchez F ^a   Velasco, M ^a   Casado, F ^a   Villa, M ^a   Vicario, J L ^a   Madero, L ^a   Lopez L M ^b  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b HOSPITAL INFANTIL UNIVERSITARIO NIÑO JESÚS   (Spain)

Author keywords

Acute lymphoblastic leukemia; Allogeneic hematopoietic cell transplantation; Chimerism

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; ETOPOSIDE; MELPHALAN; METHOTREXATE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; CHILD; CHIMERA; CLINICAL ARTICLE; EARLY DIAGNOSIS; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HEMATOPOIESIS; HIGH RISK POPULATION; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; MALE; ORAL DRUG ADMINISTRATION; PERIPHERAL BLOOD STEM CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECURRENCE RISK; RELAPSE; STEM CELL TRANSPLANTATION; VARIABLE NUMBER OF TANDEM REPEAT;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; CHIMERA; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE, L1; MALE; MINISATELLITE REPEATS; NEOPLASM, RESIDUAL; POLYMERASE CHAIN REACTION; PROSPECTIVE STUDIES; RECURRENCE; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; WHOLE-BODY IRRADIATION;

EID: 0030444338     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Gelhy GB, Bryant EM, Lee AM et al. Chimeric BCR-abl messenger RNA as a marker for minimal residual disease in patients transplanted for Philadelphia chromosome positive acute lymphoblastic leukemia. Blood 1991; 78: 458-465.
2. Kitoi H, Naoe T, Yamauchi T et al. Minimal residual disease status in pre-B acute lymphoblastic leukemia patients after chemotherapy and bone marrow transplantation: assessment of the anti-leukemic affects of chemotherapy and BMT. Leukemia Res 1993; 17: 677-684.
3. Browne PV, LLawler M, O'Riordan J et al. Early detection of leukaemic relapse after bone marrow transplantation using the polymerase chain reaction. Bone Marrow Transplant 1991; 7: 167-169.
4. McCann SR, Lawler M. Mixed chimerism; detection and significance following BMT. Bone Marrow Transplant 1993; 11: 91-94.
5. Roux E, Abdi K, Speiser D et al. Characterization of mixed chimerism in patients with chronic myeloid leukemia transplanted with T-cell-depleted bone marrow: involvement of different hematologic lineages before and after relapse. Blood 1993; 81: 243-248.
6. Roy CD, Tantravahi R, Murray C et al. Natural history of mixed chimerism after bone marrow transplantation with CD6-depleted allogenic marrow: a stable equilibrium. Blood 1990; 75: 296-304.
7. Schtenberg A, De Witte T, Salden M et al. Mixed hematopoietic chimerism after allogenic transplantation with lymphocyte-depleted bone marrow is not associated with higher incidence of relapse. Blood 1989; 73: 1367-1372.
8. Bertheas MF, Lafage M, Levy P et al. Influence of mixed chimerism on the results of allogenic bone marrow transplantation for leukemia. Blood 1991; 78: 3103-3106.
9. Katz F, Hann I. Kinsey S et al. Assessment of graft status following allogenic bone marrow transplantation for hematological disorders in children using locus-specific minisatellites probes. Br J Haematol 1993; 83: 471-479.
10. Suttorp M, Schmitz N, Dreger P et al. Monitoring of chimerism after allogenic bone marrow transplantation with unmanipulated marrow by use of DNA polymorphism. Leukemia 1993; 7: 679-687.
11. van Leeuwen JEM, van Tool MJD, Joosten AM et al. Mixed T-lymphoid chimerism after allogeneic bone marrow transplantation for hematologic malignancies of children is not correlated with relapse. Blood 1993; 82: 1921-1928.
12. van Leeuwen JEM, van Tool MJD, Joosten AM et al. Persistence of host-type hematopoiesis after allogeneic bone marrow transplantation for leukemia is significantly related to the recipient's age and/or the conditioning regimen, but it is not associated with an increased risk of relapse. Blood 1994; 83: 3059-3067.
13. Lawler M, Humphries P, McCann SR. Evaluation of mixed chimerism by in vitro amplification of dinucleotide repeat sequence using the polymerase chain reaction. Blood 1991; 77: 2504-2514.
14. Clift RA, Buckner CD, Thomas ED et al. Allogeneic marrow transplantation using fractionated total body irradiation in patients with acute lymphoblastic leukemia in relapse. Leukemia Res 1982; 6: 401-407.
15. Shank B, Chu FCH, Dinsmore R et al. Hyperfractionated total body irradiation for bone marrow transplantation, Int J Radiat Oncol Biol Phys 1981; 7: 1109-1115.
16. Tutschka PJ, Copelan EA, Klein JP. Bone marrow transplantation for leukemia following a new busulphan and cyclophosphamide regimen. Blood 1987; 70: 1382-1388.
17. Spitzer TR, Cottler-Fox M, Torrisi J et al. Escalating dose of etoposide with cyclophosphamide and fractionated total body irradiation or busulphan as conditioning for bone marrow transplantation. Bone Marrow Transplant 1989; 4: 559-565.
18. Martino R, Badell I, Brunet S et al. High-dose busulphan and melphalan before bone marrow transplantation for acute non-lymphoblastic leukemia. Bone Marrow Transplant 1995: 16; 209-212.
19. Storb R, Deeg HJ, Pepe M et al. Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukemia: long-term follow-up of controlled trial. Blood 1989; 73: 1729-1733.
20. Vogelsang GB, Morris ME. Prevention and management of graft-versus-host disease. Practical recommendations (review). Drugs 1993; 45: 668-676.
21. Thomas ED, Storb R, Clift RA et al. Bone marrow transplantation. New Engl J Med 1975; 292: 832-843.
22. Butturuni A, Gale RP. New strategies for T cell deplection. Bone Marrow Transplant 1990; 6: 225-227.
23. Maniatis T, Fritsch EF, Sambrook J. Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Laboratory Press: New York, 1982.
24. Higuchi R. Simple and rapid preparation of simples for PCR. In: Erlich HA (ed). PCR Technology. Principles and Applications for UNA Amplification. Stockton Press: New York, 1989, pp 35-36.
25. Arroyo E, García-Sánchez F, Gómez-Reino F et al. Prenatal exclusion of paternity by PCR-FLP analysis of VNRT. J Forensic Sci 1994; 39: 566-572.
26. García-Sánchez F, Díaz MA, Ramírez M et al. Minimal residual disease in childhood B lineage ALL by oligoprobes recognition of tumoral IgH-CDRIII sequences: high intensity levels are associated to relapse. Br J Haematol 1994; 87 (Suppl. 1): 442 (Abstr.).
27. Roux E, Helg C, Chapuis B et al. Evolution of mixed chimerism after allogenic bone marrow transplantation as determined on granulocytes and mononuclear cells by the polymerase reaction. Blood 1992; 79: 2775-2783.
28. van Leeuwen JEM, van Tol MJD, Bodzinga BG et al. Detection of mixed chimerism in flow-sorted cell subpopulations by PCR-amplified VNTR markers after allogeneic bone marrow transplantation. Br J Haematol 1991; 79: 218-225.
29. Ivey JN, Atchinson BA, Georgalis AM. Assessment of PCR of the D17S30 locus for forensic identification. J Forensic Sci 1994; 39: 52-63.
30. Walsh PS, Erlich HA, Higuchi R. Preferential PCR amplification of alleles: mechanism and solutions. PCR Meth Appl 1992; 1: 241-250.
31. Mackinnon S, Barnett L, Bourhis JH et al. Myeloid and lymphoid chimerism after T-cell-depleted bone marrow transplantation: evaluation of conditioning regimen using the polymerase chain reaction to amplify human minisatellite regions of genomic DNA. Blood 1992; 80: 3235-3241.
32. Bär BMAM, Schattenberg A, De Man AJM et al. Influence of the conditioning regimen on erythrocyte chimerism, graft-versus-host disease and relapse after allogeneic transplantation with lymphocyte depleted marrow. Bone Marrow Transplant 1992; 10: 45-52.
33. Mackinnon S. Barnett L, Heller G, O'Reilly RJ. Minimal residual disease is more common in patients who have mixed T-cell chimerism after bone marrow transplantation for chronic myelogenous leukemia. Blood 1994; 83: 3409-3416.
34. Socié G, Gluckman E, Rayani B et al. Short-term study of chimaerism after bone marrow transplantation for severe aplastic anaemia. Br J Haematol 1992; 80: 391-398.